BACKGROUND: Current exercise guidelines for clinical populations recommend an exercise therapy (ET) prescription of fixed intensity (moderate), duration (40-50 minutes per session), and volume (120-160 min/wk). A critical overarching element of exercise programming that has received minimal attention is dose scheduling. We investigated the tolerability and efficacy of 2 exercise training dose regimens on cardiorespiratory fitness and patient-reported outcomes in patients with posttreatment primary breast cancer. METHODS: Using a parallel-group randomized trial, we randomly allocated 174 postmenopausal patients (2.8 years afteradjuvant therapy) with impaired peak oxygen consumption (VO2peak) to 1 of 2 supervised exercise training interventions delivered with a standard linear (LET) (fixed dose intensity per session for 160 min/wk) or nonlinear (NLET) (variable dose intensity per session for ≈120 min/wk) schedule compared with a stretching attention control group for 16 consecutive weeks. Stretching was matched to exercise dosing arms on the basis of location, frequency, duration, and treatment length. The primary end point was change in VO2peak (mL O2·kg-1·min-1) from baseline to after intervention. Secondary end points were patient-reported outcomes, tolerability, and safety. RESULTS: No serious adverse events were observed. Mean attendance was 64%, 75%, and 80% for attention control, LET, and NLET, respectively. In intention-to-treat analysis, VO2peak increased 0.6±1.7 mL O2·kg-1·min-1 (P=0.05) and 0.8±1.8 mL O2·kg-1·min-1 (P=0.07) in LET and NLET, respectively, compared with attention control. Change in VO2peak ranged from -2.7 to 4.1 mL O2·kg-1·min-1 and from -3.6 to 5.1 mL O2·kg-1·min-1 in LET and NLET, respectively. Approximately 40% of patients in both exercise dosing regimens were classified as VO2peak responders (ie, Δ ≥1.32 mL O2·kg-1·min-1). NLET improved all patient-reported outcomes compared with attention control. CONCLUSIONS:Short-term exercise training, independently of dosing schedule, is associated with modest improvements in cardiorespiratory fitness in patients previously treated for early-stage breast cancer. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01186367.
RCT Entities:
BACKGROUND: Current exercise guidelines for clinical populations recommend an exercise therapy (ET) prescription of fixed intensity (moderate), duration (40-50 minutes per session), and volume (120-160 min/wk). A critical overarching element of exercise programming that has received minimal attention is dose scheduling. We investigated the tolerability and efficacy of 2 exercise training dose regimens on cardiorespiratory fitness and patient-reported outcomes in patients with posttreatment primary breast cancer. METHODS: Using a parallel-group randomized trial, we randomly allocated 174 postmenopausal patients (2.8 years after adjuvant therapy) with impaired peak oxygen consumption (VO2peak) to 1 of 2 supervised exercise training interventions delivered with a standard linear (LET) (fixed dose intensity per session for 160 min/wk) or nonlinear (NLET) (variable dose intensity per session for ≈120 min/wk) schedule compared with a stretching attention control group for 16 consecutive weeks. Stretching was matched to exercise dosing arms on the basis of location, frequency, duration, and treatment length. The primary end point was change in VO2peak (mL O2·kg-1·min-1) from baseline to after intervention. Secondary end points were patient-reported outcomes, tolerability, and safety. RESULTS: No serious adverse events were observed. Mean attendance was 64%, 75%, and 80% for attention control, LET, and NLET, respectively. In intention-to-treat analysis, VO2peak increased 0.6±1.7 mL O2·kg-1·min-1 (P=0.05) and 0.8±1.8 mL O2·kg-1·min-1 (P=0.07) in LET and NLET, respectively, compared with attention control. Change in VO2peak ranged from -2.7 to 4.1 mL O2·kg-1·min-1 and from -3.6 to 5.1 mL O2·kg-1·min-1 in LET and NLET, respectively. Approximately 40% of patients in both exercise dosing regimens were classified as VO2peak responders (ie, Δ ≥1.32 mL O2·kg-1·min-1). NLET improved all patient-reported outcomes compared with attention control. CONCLUSIONS: Short-term exercise training, independently of dosing schedule, is associated with modest improvements in cardiorespiratory fitness in patients previously treated for early-stage breast cancer. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01186367.
Entities:
Keywords:
breast neoplasms; cardiorespiratory fitness; exercise
Authors: Tormod S Nilsen; Jessica M Scott; Meghan Michalski; Catherine Capaci; Samantha Thomas; James E Herndon; John Sasso; Neil D Eves; Lee W Jones Journal: Med Sci Sports Exerc Date: 2018-06 Impact factor: 5.411
Authors: Jessica M Scott; Neil M Iyengar; Tormod S Nilsen; Meghan Michalski; Samantha M Thomas; James Herndon; John Sasso; Anthony Yu; Sarat Chandarlapaty; Chau T Dang; Elizabeth A Comen; Maura N Dickler; Jeffrey M Peppercorn; Lee W Jones Journal: Cancer Date: 2018-04-06 Impact factor: 6.860
Authors: Mansueto Gomes-Neto; André R Durães; Helena F Correia Dos Reis; Victor R Neves; Bruno P Martinez; Vitor O Carvalho Journal: Eur J Prev Cardiol Date: 2017-08-21 Impact factor: 7.804
Authors: Michel G Khouri; Pamela S Douglas; John R Mackey; Miguel Martin; Jessica M Scott; Marielle Scherrer-Crosbie; Lee W Jones Journal: Circulation Date: 2012-12-04 Impact factor: 29.690
Authors: Graeme J Koelwyn; Nia C Lewis; Susan L Ellard; Lee W Jones; Jinelle C Gelinas; J Douglass Rolf; Bernie Melzer; Samantha M Thomas; Pamela S Douglas; Michel G Khouri; Neil D Eves Journal: Oncologist Date: 2016-01-13
Authors: Øyvind Ellingsen; Martin Halle; Viviane Conraads; Asbjørn Støylen; Håvard Dalen; Charles Delagardelle; Alf-Inge Larsen; Torstein Hole; Alessandro Mezzani; Emeline M Van Craenenbroeck; Vibeke Videm; Paul Beckers; Jeffrey W Christle; Ephraim Winzer; Norman Mangner; Felix Woitek; Robert Höllriegel; Axel Pressler; Tea Monk-Hansen; Martin Snoer; Patrick Feiereisen; Torstein Valborgland; John Kjekshus; Rainer Hambrecht; Stephan Gielen; Trine Karlsen; Eva Prescott; Axel Linke Journal: Circulation Date: 2017-01-12 Impact factor: 29.690
Authors: Meghan Michalski; Kylie Rowed; Jessica A Lavery; Chaya S Moskowitz; Catherine Capaci; Guro Stene; Elisabeth Edvardsen; Neil D Eves; Lee W Jones; Jessica M Scott Journal: JACC CardioOncol Date: 2022-06-21
Authors: Joshua W Bliss; Jessica A Lavery; Whitney P Underwood; Su S Chun; Gina A Fickera; Catherine P Lee; Stacie Corcoran; Molly A Maloy; Fernanda C Polubriaginof; Daniel W Kelly; Jessica M Scott; Paul C Boutros; Chaya S Moskowitz; Lee W Jones Journal: Cancer Epidemiol Biomarkers Prev Date: 2022-05-04 Impact factor: 4.090
Authors: Michael R Harrison; Paul G Davis; Michel G Khouri; David B Bartlett; Rajan T Gupta; Andrew J Armstrong; Megan A McNamara; Tian Zhang; Monika Anand; Kelly Onyenwoke; Sara Edwardson; Danielle Craig; Meghan Michalski; Yuan Wu; Taofik Oyekunle; Brian Coyne; Aubrie Coburn; Lee W Jones; Daniel J George Journal: Prostate Cancer Prostatic Dis Date: 2022-03-10 Impact factor: 5.554
Authors: Jessica M Scott; Samantha M Thomas; James E Herndon; Pamela S Douglas; Anthony F Yu; Valerie Rusch; James Huang; Catherine Capaci; Jenna N Harrison; Kurtis J Stoeckel; Tormod Nilsen; Elisabeth Edvardsen; Meghan G Michalski; Neil D Eves; Lee W Jones Journal: J Cachexia Sarcopenia Muscle Date: 2021-10-17 Impact factor: 12.910
Authors: Niklas Paul Grusdat; Alexander Stäuber; Marion Tolkmitt; Jens Schnabel; Birgit Schubotz; Peter Richard Wright; Henry Schulz Journal: Support Care Cancer Date: 2022-01-11 Impact factor: 3.359
Authors: Jordan T Lee; Chad W Wagoner; Stephanie A Sullivan; Dean J Amatuli; Kirsten A Nyrop; Erik D Hanson; Lee Stoner; Brian C Jensen; Hyman B Muss; Claudio L Battaglini Journal: World J Clin Oncol Date: 2021-06-24
Authors: Salvatore Ficarra; Ewan Thomas; Antonino Bianco; Ambra Gentile; Petra Thaller; Fulvio Grassadonio; Sofia Papakonstantinou; Thorsten Schulz; Nils Olson; Alexandra Martin; Christian Wagner; Anna Nordström; Hande Hofmann Journal: Breast Cancer Date: 2022-03-12 Impact factor: 3.307